Proinflammatory cytokine production inhibition

Proinflammatory cytokine production inhibition refers to the therapeutic or physiological suppression of key signaling proteins (cytokines) involved in mediating inflammatory responses, notably TNF-α, IL-1β, and IL-6[7][1][3][4]. This process can be achieved through direct action on cytokine-producing cells (e.g., monocytes/macrophages), interference with upstream signaling pathways (such as NF-κB, Jak/STAT, NLRP3 inflammasome activation), or via exogenous drugs or endogenous molecules (e.g., spermine, anti-cytokine antibodies)[1][2][3][4][5][6]. The inhibition is critical for preventing tissue damage and resolving inflammation but comes with therapeutic challenges such as potential immunosuppression and increased infection risk[7][5]. The entry "Proinflammatory cytokine production inhibition" does not reference a specific target but encompasses multiple molecular entities and pathways involved in immune regulation.

Other names

Suppression of proinflammatory cytokine productionCytokine inhibitionBlockade of inflammatory cytokinesInhibition of TNF/IL-1/IL-6

Inhibition of transcription or translation of cytokine genes; Disruption of Jak/STAT, NF-κB, or inflammasome signaling; Posttranscriptional suppression (e.g., spermine); Receptor antagonism (e.g., IL-1 receptor antagonists); Free radical scavenging; Induction of anti-inflammatory autocrine/paracrine signals (TGF-beta, PGE2, PAF)